Series B Co-led by New Investors Amplitude Ventures and ICG
MTX-474 Global Phase 2a study Initiated in Systemic Sclerosis (SSc)
MTX-463 Global Phase 2a Study in Idiopathic…
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
